Board of Directors
T-CURX’s Board of Directors combines deep sector expertise, strong network, and a proven track record in supporting the growth of innovative biopharmaceutical companies.
Hans-Peter Gerber, PhD
Chairman of the BoardHans-Peter is an industry veteran and internationally recognized leader with more than 25 years of R&D experience in oncology drug development, including antibody-drug conjugates (ADCs), T-cell engagers (TCEs, “bispecifics”) and adoptive T-cell therapies (TCR-T and CAR-T cells).
Bernd Eschgfäller, PhD
Board MemberBernd brings over 20 years of Novartis experience in CAR-T therapy development and commercialization, including his instrumental role in the launch of Kymriah®, the first FDA-approved CAR-T cell product.
Aristotelis Nastos, PhD
Board MemberAristotelis is a venture capital investor and Managing Partner at BioMedVC, specializing in building and backing breakthrough life sciences companies—from early-stage to global scale-up.
Xijin Xu, PhD
Board MemberXijin, Associate Director at HighLight Capital, specializes in early-stage healthcare and biotech investments, leveraging her deep expertise in immunology and life-science opportunities, while serving on the boards of portfolio companies to drive strategic growth.
Jörg Neermann, PhD
Board MemberJörg combines deep venture capital expertise as a former Partner at leading European life sciences investment firm LSP with hands-on startup leadership, having built a biotech company from inception to clinical readiness.
Henning Schwanhäusser
Board MemberHenning is a serial entrepreneur and investor with a track record in biotech, including co-founding and shaping the strategy of NBE-Therapeutics, which was acquired by Boehringer Ingelheim for $1.4 billion in 2021.
Learn more about our
Scientific Advisory Board →
Our Investors
In December 2025, T-CURX announced the first closing of its $20M (€17.7M) Series A financing with a syndicate of European and Asian investors to accelerate the development of T-CURX’s non-viral clinical CAR-T therapies in AML and solid tumor indications, as well as to advance T-CURX’s proprietary non-viral technologies for in vivo CAR-T generation.
